Fondaparinux
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Fondaparinux: From Anticoagulant Therapy to Primary Release Disorder of Platelets
One-Sentence Summary
Fondaparinux is a synthetic pentasaccharide anticoagulant (Factor Xa inhibitor); the evidence pack does not contain a formal original-indication text or DrugBank MOA record. TxGNN predicts possible relevance to Primary Release Disorder of Platelets, but the only supporting evidence retrieved (2 clinical trials, 2 publications) actually concerns heparin-induced thrombocytopenia (HIT), not platelet release disorders — a likely disease-label mismatch flagged directly in the evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (pharmacologically an anticoagulant / Factor Xa inhibitor, per rationale text) |
| Predicted New Indication | Primary Release Disorder of Platelets |
| TxGNN Prediction Score | 93.06% |
| Evidence Level | L3 |
| Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no structured mechanism-of-action record is available for Fondaparinux (original_moa = Data Gap). However, the repurposing rationale collected as part of this evidence pack does describe the mechanism: Fondaparinux is a synthetic pentasaccharide that selectively inhibits Factor Xa via antithrombin binding, and it does not bind platelet factor 4 (PF4). Because of this, it does not cross-react with heparin-induced thrombocytopenia (HIT) antibodies, and it is already used clinically as an alternative anticoagulant in HIT patients.
The predicted new indication, “primary release disorder of platelets,” refers to a primary defect in platelet granule release (e.g., storage pool disease) — a mechanistically distinct condition from HIT. Both retrieved clinical trials and one of the two retrieved publications concern HIT, not platelet release disorders. This strongly suggests an ontology/disease-label mismatch between the TxGNN node and the retrieved evidence, exactly as noted in the pack’s own rationale text. The mechanistic plausibility of fondaparinux for HIT-related anticoagulation is real and well-established; its plausibility for a genuine primary platelet-release disorder is not supported by any evidence in this pack and would need a separate, correctly targeted evidence search.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00911300 | Phase 2 | Completed | 349 | International multicentre RCT comparing fondaparinux vs. heparin/vitamin-K antagonists for anticoagulation in atrial fibrillation patients undergoing electric cardioversion. Relevance grade B — mechanistically tied to fondaparinux’s low HIT cross-reactivity, but not a direct study of platelet release disorder. |
| NCT01178333 | N/A (retrospective) | Completed | 668 | Retrospective analysis of HIT incidence and outcomes (HIT-RADIO study) using existing medical records (platelet counts, treatments, outcomes). Relevance grade C — background epidemiology only, non-interventional, no direct causal support. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28646118 | 2017 | Review | Blood | Review of direct oral anticoagulants for HIT treatment, updating the Hamilton group’s clinical experience; not specific to platelet release disorders. |
| 30018843 | 2017 | Case Report | Journal of the Advanced Practitioner in Oncology | Case study on palliative chemotherapy in a patient with metastatic adenocarcinoma; unrelated to Fondaparinux or platelet mechanisms — appears to be a low-relevance/mismatched retrieval. |
Market Information
Fondaparinux is currently not marketed in this jurisdiction, with 0 authorizations on record. No product license data is available to summarize.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: key_warnings, contraindications, and DDI data were all unavailable in this evidence pack; DDI query returned “not_found.”)
Conclusion and Next Steps
Decision: Hold
Rationale: The only clinical/literature evidence retrieved supports fondaparinux’s known role in HIT-related anticoagulation, not the specifically predicted “primary release disorder of platelets” — the pack itself flags this as a likely ontology mismatch requiring manual confirmation. Combined with a blocking data gap on TFDA warnings/contraindications (DG001) and the drug not currently being marketed in this jurisdiction, the evidence base does not yet support advancing this candidate.
To proceed, the following is needed:
- TFDA label (warnings/contraindications) to clear the blocking S1 safety gap (DG001)
- Verified DrugBank MOA record (DG002)
- Manual review confirming whether the TxGNN “primary release disorder of platelets” node genuinely maps to the retrieved HIT trials, or whether a corrected, disease-specific evidence search is required
- Market-entry feasibility assessment, given zero current authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.